Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated at began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report published on Sunday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Shares of NYSE NAVB opened at $0.05 on Friday. The company has a market cap of $5.00 million, a PE ratio of -0.17 […]

Leave a Reply

Your email address will not be published.

Previous post MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at
Next post Cellectis (NASDAQ:CLLS) Research Coverage Started at